1-8 of 8
Larry W Buie, PharmD, BCOP
Close
Sort by
Journal Articles

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Katrina M Piedra, PharmD, Hani Hassoun, MD, Larry W. Buie, PharmD, BCOP, FASHP, Sean M. Devlin, PhD, Jessica Flynn, BS, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sydney X Lu, MD PhD, Sham Mailankody, MBBS, Urvi A Shah, MD, Eric L Smith, MD PhD, Ola Landgren, MD PhD, Neha Korde, MD, Tim J Peterson, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1835.
https://doi.org/10.1182/blood-2019-124403
Published: 2019
Journal Articles

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Charlene C. Kabel, PharmD, Debra A. Goldman, MS, Larry W. Buie, PharmD, BCOP, FASHP, Virginia M. Klimek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1718.
https://doi.org/10.1182/blood-2019-129129
Published: 2019
Journal Articles

Effect of Obesity on the Efficacy and Toxicities in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) for Lymphoma

Nicole Pearl, PharmD, Andrew Lin, PharmD, BCOP, Patrick Hilden, MS, Larry W Buie, PharmD, BCOP, FASHP, Kevin Robinson, Molly Maloy, MS, Gunjan L. Shah, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4617.
https://doi.org/10.1182/blood-2018-99-119554
Published: 2018
Journal Articles

Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Aaron D Goldberg, MD, Troy Z. Horvat, PharmD, BCOP, Meier Hsu, MS, Sean M. Devlin, PhD, Bernadette M. Cuello, BSN, MSN, NP, RN, Ryan J. Daley, PharmD, BCOP, Amber C. King, PharmD, BCOP, Larry W Buie, PharmD, BCOP, FASHP, Jacob L Glass, MDPhD, Michael J. Mauro, MD, Eytan M. Stein, MD, Ellin Berman, MD, Virginia M. Klimek, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1353.
https://doi.org/10.1182/blood.V130.Suppl_1.1353.1353
Published: 2017
Journal Articles

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Jeremy Pappacena, PharmD, Valkal Bhatt, PharmD, BCOP, BCPS, Gunjan L. Shah, MD, Patrick Hilden, MS, Molly Maloy, MS, Larry W Buie, PharmD, BCOP, FASHP, Sergio A. Giralt, MD, Michael Scordo, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1950.
https://doi.org/10.1182/blood.V130.Suppl_1.1950.1950
Published: 2017
Journal Articles

Risk of Hyponatremia and Associated Clinical Characteristics in Patients with Acute Lymphoblastic Leukemia after CD19 Targeted Chimeric Antigen Receptor (CAR) T-Cells

Brianne N. Dixon, PharmD, Ryan J. Daley, PharmD, BCOP, Troy Z. Horvat, PharmD, BCOP, Larry W Buie, PharmD, BCOP, FASHP, Meier Hsu, MS, Sheron Latcha, MD, Renier J. Brentjens, MD PhD, Jae H. Park, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3584.
https://doi.org/10.1182/blood.V130.Suppl_1.3584.3584
Published: 2017
Journal Articles

Erwinia Asparaginase Safety and Feasibility during Therapy for Acute Lymphoblastic Leukemia in Adult Patients with Pegaspargase Hypersensitivity or Severe Toxicity

Troy Z Horvat, PharmD, BCOP, Joshua J Pecoraro, PharmD, BCOP, Ryan J Daley, PharmD, BCOP, Larry W Buie, PharmD, BCOP, Dan Douer, MD
Journal: Blood
Blood (2015) 126 (23): 4915.
https://doi.org/10.1182/blood.V126.23.4915.4915
Published: 2015
Journal Articles

Hypoalbuminemia Is Significantly Associated with Increased Clearance Time of High Doses of Methotrexate

Samantha N. Reiss, PharmD, Larry W. Buie, PharmD, BCOP, Nelly G. Adel, PharmD, BCOP, BCPS, Debra A. Goldman, MS, Sean Devlin, PhD, Dan Douer, MD
Journal: Blood
Blood (2015) 126 (23): 3711.
https://doi.org/10.1182/blood.V126.23.3711.3711
Published: 2015